by Ludwig Cancer Research Credit: CC0 Public Domain The cells of a subset of myeloproliferative neoplasms (MPNs), slow-growing blood cancers, have frameshift mutations in their calreticulin (CALR) gene that are associated with the disease. The tail end of this gene’s mutated protein product (CALRMUT) should be an ideal neoantigen. Yet T cells directed against the CALRMUT fragment...
